Dopamine Capsules

This product is a compound preparation, containing levodopa and benserazide. Benserazide is a peripheral decarboxylase inhibitor, which is not easy to enter the central nervous system. It only inhibits the conversion of peripheral levodopa into dopamine, increasing the content of levodopa in the circulation by 5-10 times, and thus the amount of levodopa entering the central nervous system also increases. Levodopa is converted into dopamine by dopa decarboxylase in the brain to exert its pharmacological effects and improve the symptoms of Parkinson's disease. The combination of benserazide and levodopa can not only reduce the adverse reactions of levodopa in the peripheral cardiovascular system, but also reduce the dosage of levodopa.

This product is a compound preparation, its components are: levodopa and benserazide hydrochloride.

This product is in the form of capsules.

Used for Parkinson's disease and Parkinson's syndrome.

Take orally 125 mg twice a day in the first week; increase by 125 mg every other week thereafter. Generally, the daily dose should not exceed 1 g, divided into 3 to 4 doses. The maintenance dose is 250 mg once, 3 times a day.

The more common adverse reactions are nausea, vomiting, orthostatic hypotension, abnormal involuntary movements of the head, face, tongue, upper limbs and upper body, depression, and dysuria. Less common adverse reactions are hypertension, arrhythmia, and hemolytic anemia.

It is contraindicated for patients with severe mental illness, severe arrhythmia, heart failure, glaucoma, peptic ulcer and a history of convulsions.

Precautions for children: Use with caution. Precautions for pregnancy and lactation: This product can be secreted into breast milk and can also reduce breast milk secretion; animal experiments have shown that this product can cause visceral and skeletal deformities. Pregnant and lactating women should not use it. Precautions for the elderly: Not yet clear.

1. This product combined with non-selective monoamine oxidase inhibitors may cause acute adrenal crisis. 2. This product combined with papaverine or vitamin B6 may reduce the efficacy of this product. 3. This product combined with acetylspiramycin can significantly reduce the blood concentration of this product and weaken the efficacy. 4. This product combined with reserpine can inhibit the effect of this product and should be avoided. 5. This product combined with antipsychotic drugs should be avoided because the two antagonize each other. 6. This product combined with methyldopa can increase the adverse reactions of this product and enhance the antihypertensive effect of methyldopa.

Keep away from light, tightly closed, in a cool and dry place.

0.25 g (levodopa: 0.2 g, benserazide: 50 mg)

24 months

Guangzhou Hanfang Pharmaceutical Company Limited

• Founded in:

  1998-09-24

• Address:

  No. 8 Wenquan Avenue, Conghua, Guangzhou

• Tax NO.:

  914401017124186087

• Registered Funds:

  252.5643 million yuan

• Website:

  Log in to view

• Email:

  Log in to view